Could a fish oil supplement help kids with speech apraxia?
NCT ID NCT07216001
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This study tests an investigational drug called Omega-DEK plus L-carnitine in 34 children aged 3 to 6 with childhood apraxia of speech (CAS). The study lasts 20 weeks and first gives everyone the treatment, then randomly assigns some to a placebo to see if the treatment helps maintain speech gains. The main goal is to see if this approach is feasible and acceptable for families.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Healthcare of Atlanta
Atlanta, Georgia, 30322, United States
-
Marcus Autism Center
Atlanta, Georgia, 30329, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gentle massage and calming sounds: a new bedtime ritual for autistic kids?
- Can a camera catch autism signs in preemie toddlers?
- Can a new curriculum help autistic adults navigate romance?
- Can a parent support group help teens with both autism and anorexia?
- Could moving mindfully boost social skills in adults with autism?
- Can a gene mutation explain Autism's many faces?